Company Description
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.
In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model.
Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services.
The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model.
It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use.
The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012.
Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jul 2, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 6,140 |
| CEO | Steven Chapman |
Contact Details
Address: 13011 McCallen Pass, Building A Austin, Texas 78753 United States | |
| Phone | 650 980 9190 |
| Website | natera.com |
Stock Details
| Ticker Symbol | NTRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604821 |
| CUSIP Number | 632307104 |
| ISIN Number | US6323071042 |
| Employer ID | 01-0894487 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Steven Leonard Chapman | Chief Executive Officer and Director |
| Dr. Matthew Rabinowitz Ph.D. | Co-Founder and Executive Chairman |
| John Fesko | President and Chief Business Officer |
| Michael B. Brophy M.B.A. | Chief Financial Officer |
| Solomon Moshkevich M.B.A. | President of Clinical Diagnostics |
| Jonathan Sheena M.Eng. | Co-Founder and Director |
| Olesya A. Anisimova CPA | Chief Accounting Officer |
| Rishi Kacker | Chief Technology Officer |
| Eric A. Evans Ph.D. | Chief Scientific Officer |
| Daniel Rabinowitz L.L.M. | Secretary and Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | 144 | Filing |
| Mar 18, 2026 | 144 | Filing |
| Mar 13, 2026 | 144 | Filing |
| Mar 12, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2026 | 10-K | Annual Report |